Teledyne reports all-time best quarter sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stroke care major focus at annual neuro symposium
In an effort to continue discussing some of the latest advancements and knowledge about topics in neurocare, Adventist Health is hosting its fourth annual Central Coast Neuroscience Symposium led by distinguished experts on Oct. 30. The conference will deliver evidence-based updates to enhance stroke clinical knowledge — from triage, to surgery, endovascular therapy, bedside care, Read More →
New breast cancer prevention, treatment programs unveiled on Central Coast
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Report: Aerospace employs 80,000 in tri-county region
A new report makes the case that with 7,000 companies employing some 80,000 workers, the region should be recognized as a major hub for aerospace and autonomous systems. Called “The Central Coast: Built to Prove What’s Next,” the report catalogues a number of familiar assets and some new initiatives. The report was released by a Read More →
New Westlake Village biotech center could see first tenants in 2027
Life sciences tenants could begin moving into a new biotech center in Westlake Village as soon as next year. The approximately 100,000-square-foot property was acquired in early 2023 by San Francisco-based Graymark Capital in partnership with Argosy Real Estate Partners. The former headquarters of Anthem Blue Cross, the facility, now named Westlake Labs, has been Read More →
Atara receives action date for tabcel
Thousand Oaks-based Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, received acceptance by the U.S. Food and Drug Administration of the Biologics License Application for tabelecleucel, Atara’s lead product, on Oct. 14. With the notice, the FDA also set a target action date for the drug on March 31. Tabelecleucel, sold under the brand Read More →
Moorpark College, CSUCI partner on new bachelor program in cybersecurity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
